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Sung Hoon Noh1,5, Sangwoo Kim4 & Jae-Ho Cheong1,2,5,6,8
The patient-derived xenograft (PDX) model is emerging as a promising translational platform to 
duplicate the characteristics of tumours. However, few studies have reported detailed histological 
and genomic analyses for model fidelity and for factors affecting successful model establishment of 
gastric cancer. Here, we generated PDX tumours surgically-derived from 62 gastric cancer patients. 
Fifteen PDX models were successfully established (24.2%, 15/62) and passaged to maintain tumours in 
immune-compromised mice. Diffuse type and low tumour cell percentage were negatively correlated 
with success rates (p = 0.005 and p = 0.025, respectively), while reducing ex vivo and overall procedure 
times were positively correlated with success rates (p = 0.003 and p = 0.01, respectively). The histology 
and genetic characteristics of PDX tumour models were stable over subsequent passages. Lymphoma 
transformation occurred in five cases (33.3%, 5/15), and all were in the NOG mouse, with none in the 
nude mouse. Together, the present study identified Lauren classification, tumour cell percentages, and 
ex vivo times along with overall procedure times, as key determinants for successful PDX engraftment. 
Furthermore, genetic and histological characteristics were highly consistent between primary and PDX 
tumours, which provide realistic paraclinical models, enabling personalised development of treatment 
options for gastric cancer.
Gastric cancer is one of the most important health problems in the world; it is the 5th most commonly diagnosed 
cancer and the 3rd most common cause of death from cancer1. For advanced gastric cancer, additional treatment 
followed by surgical resection is mandatory, but the clinical response to standard chemotherapy varies among 
patients, and biologically-targeted therapeutics are rarely utilized2–7. These heterogeneous treatment outcomes 
and lack of clinically usable targeted therapeutics represent urgent clinical needs, and emphasize the necessity 
of developing effective personalized treatments for patients with gastric cancer, based on the tumour’s molecular 
and genetic characteristics. To achieve effective cancer therapies, more realistic models based on the biological 
characteristics of individual patients are needed to predict the response to therapy. Traditionally, cancer cell lines 
and xenograft models derived from the established cell lines have been used for drug screening, to characterise 
the biology of specific tumours and to identify optimal drug candidates for therapy. Despite several advantages, 
the monodimensionality of cells grown in culture, and xenograft models that have adapted to growth in artificial 
culture conditions, largely differ from primary tumours8. They poorly represent the heterogeneity and genetic 
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features of patient tumours. Consequently, predictive values for clinical outcomes, based upon these systems, have 
been largely unsatisfactory9,10.
Patient-derived xenograft (PDX) tumours, which are xenograft models developed by transplanting human 
tumours into immune-compromised mice, have been suggested as a more realistic preclinical cancer model11,12. 
PDX tumours retain the majority of key genes expressed in primary tumours8,13, and they correlate well with 
clinical responses to chemotherapy14,15. Recently, there has been renewed interest in establishment of PDX mod-
els for various cancers by investigators in academic and pharmaceutical research, to improve the development 
of effective therapeutics16–18. Despite the potential importance of the PDX model for cancer research and clinical 
translation, few studies have reported histological and genomic fidelities of the model systems, and few reports 
have identified factors correlated with engraftment success of gastric PDX tumours. The purpose of the present 
study was therefore to characterise the histological and genomic fidelities of gastric cancer PDX models and iden-
tify the factors related to the successful engraftment in mice.
Results
Baseline characteristics. To establish PDX tumours, a total of 161 mice (75 nude mice and 86 NOG mice) 
were used as recipients of tumours from 62 gastric cancer patients. The baseline characteristics of donor patients 
are summarized in Supplementary Table S1. The median patient age was 61 years, and 77.4% (48 out of 62) 
were male. Thirty-eight (61.3%) patients were diagnosed as stage I/II, and the other patients were diagnosed as 
stage III/IV (37.1%). There were 30 patients (48.4%) with lymph node metastasis. Thirty-six (58.1%) patients had 
undifferentiated histology, while 19 (30.6%) and 5 (8.1%) patients had differentiated histology, with carcinomas 
with lymphoid stroma or mixed histology, respectively. There were 32 cases (51.6%) of intestinal tumours, 18 
cases (29.0%) of diffuse tumours, and 10 cases (16.1%) of mixed or indeterminate tumours.
Establishment of PDX models. PDX tumours were initially generated in F1 mice, then implanted into 
F2 mice in 15 cases (24.2%, 15 out of 62). Table 1 summarizes the characteristics of these successful cases. The 
histological types were poorly differentiated (n = 5), moderately differentiated (n = 6), mucinous (n = 2), mod-
erately differentiated with signet ring cells (n = 1), and mixed adeno-neuroendocrine (n = 1) carcinomas. Using 
the Lauren classification19, 12 tumours were intestinal, two tumours were indeterminate, and one tumour was 
mixed. The implantation locations for F1 in successful engraftment cases were subcutaneous of the flank in 14 
mice, and the subrenal capsule in one mouse. The recipient mouse strains were six nude mice and nine NOG 
mice. The median percentage of tumour cells in the tissue fragments was 60% (5–90%), and the median elapsed 
time for engraftment in F1 animals was 94 days (44–160 days). The details of the growth rate in F1 animals are 
shown in Supplementary Fig. S1. There was no difference between the nude and NOG mice regarding growth 
rates and elapsed time.
Factors related to successful engraftment of PDX tumours. To investigate potential factors related 
to the success of PDX tumours, we classified the parameters into three groups: patient characteristics, patho-
logical tumour characteristics, and experimental parameters. There were no statistically significant parameters 
correlated with success of PDX tumours in patient characteristics such as age, gender, co-morbidity, history of 
smoking and alcohol, and no statistically significant parameters correlated with the success of PDX tumours in 
laboratory parameters, including tumour markers such as carcinoembryonic antigen (CEA) and carbohydrate 
Case No. Age Sex Histology Lauren
F1 mouse
% of tumour cells Strain Implanted site
Duration in F1 
(days)†
GA001 72 F Mixed* Indeterminate 30 NOG subcutaneous 101
GA003 54 M MD Intestinal 5 NOG subcutaneous 94
GA006 73 M PD Intestinal 60 nude subcutaneous 95
GA013 79 M PD Intestinal 90 nude subcutaneous 70
GA018 78 F PD Intestinal 80 NOG subrenal capsule 99
GA026 61 M MD Mixed 50 NOG subcutaneous 160
GA044 67 M MD Intestinal 20 nude subcutaneous 125
GA046 62 M MD Intestinal 90 NOG subcutaneous 139
GA051 52 F Mucinous Intestinal 50 NOG subcutaneous 70
GA052 61 F Mucinous Intestinal 70 nude subcutaneous 112
GA054-1 48 M MD Intestinal NA NOG subcutaneous 91
GA054-2 59 F PD Indeterminate 90 NOG subcutaneous 48
GA058 67 M PD Intestinal 70 nude subcutaneous 76
GA060 80 M MD Intestinal 60 nude subcutaneous 44
GA061 54 F MD with SRC component Intestinal 10 (SRC only) NOG subcutaneous 57
Table 1.  Summary of characteristics of established PDX models for gastric cancer. *Adeno-neuroendocrine 
mixed carcinoma. †Interval between implantation and subpassage to F2. M, male; F, female; MD, moderately 
differentiated tubular adenocarcinoma; PD, poorly differentiated tubular adenocarcinoma; SRC, signet ring cell; 
NOG, NOD/Shi-scid/IL-2 Rγ null mouse; NA, not available.
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antigen 19–9 (CA19–9) (Supplementary Table S2). Regarding tumour pathological characteristics, the location, 
gross type, tumour aggressiveness such as tumour size, invasion depth, lymph node metastasis, and TNM stage, 
and preoperative chemotherapy were not correlated with engraftment success (Table 2). There were no engraft-
ment successes among 18 cases of the diffuse type of gastric cancer, while PDX tumours were established in 12 
(37.5%) out of 32 cases of intestinal tumours, and 3 (30%) out of 10 cases of mixed or indeterminate type tumours 
(p = 0.005). In addition, higher tumour cell percentages in the representative tissues were correlated with higher 
success rates (p = 0.025).
Among the experimental parameters, ex vivo times were shorter in successful cases than unsuccessful cases 
(median time was 75 minutes for successful cases versus 135 minutes for unsuccessful cases, p = 0.003, Table 3). In 
addition, a short overall procedure time correlated with engraftment success (123 minutes for successful engraft-
ments versus 167 minutes for unsuccessful engraftments, p = 0.01). When multiple pieces were implanted in a 
single animal, the success rate was higher (38.9%) than for implantation of a single piece (18.2%), but this dif-
ference was not statistically significant (p = 0.108). Other experimental parameters, such as the mouse strain, 
implantation site, or using Matrigel were not correlated with engraftment success (they were analysed based on 
the number of mice). The success rate was 8.0% for nude mice (6 out of 75) and 10.5% for NOG mice (9 out of 
Variables
Number (%)
p-valueSuccessful (n = 15) Unsuccessful (n = 47)
Size (mm)† 55 (23–110) 50.0 (15–167) 0.619
Location 0.791
 Upper 3 (20.0) 14 (29.8)
 Middle/Lower 11 (73.3) 30 (63.8)
 Others (whole, RGC) 1 (6.7) 3 (6.4)
Gross type 0.321
 EGC 9 (60.0) 18 (38.3)
 Borrman I/II 5 (33.3) 20 (42.6)
 Borrman III/IV 1 (6.7) 9 (19.1)
pT stage* > 0.999
 pT1/2 5 (33.3) 15 (33.3)
 pT3/4 10 (66.7) 30 (66.7)
LN metastasis 0.660
 negative 7 (46.7) 25 (53.2)
 positive 8 (53.3) 22 (46.8)
pTNM stage* 0.353
 I/II 8 (53.3) 30 (66.7)
 III/IV 7 (46.7) 15 (33.3)
Histology* 0.301
 Differentiated 7 (46.7) 12 (26.7)
 Undifferentiated 7 (46.7) 29 (64.4)
 Others‡ 1 (6.7) 4 (8.9)
Lauren* 0.005
 Intestinal 12 (80.0) 20 (44.4)
 Diffuse 0 (0) 18 (40.0)
 Others (mixed & indeterminate) 3 (32.0) 7 (15.6)
LVI* 0.554
 No 7 (46.7) 26 (57.8)
 Yes 8 (53.3) 19 (42.2)
PNI* 0.238
 No 10 (66.7) 21 (46.7)
 Yes 5 (33.3) 24 (53.3)
Preoperative chemotherapy 0.626
 No 13 (86.7) 43 (91.5)
 Yes 2 (13.3) 4 (8.5)
Variables° Successful (n = 15) Unsuccessful (n = 97) p-value
% of tumour cells† 60 (5–90) 30 (0–90) 0.025
Table 2.  Pathological characteristics related to engraftment success of PDX tumours of gastric cancer. 
*There was complete pathologic regression of tumours after preoperative chemotherapy in two patients. 
†Median with range. ‡Lymphoepithelioma-like carcinoma (carcinoma with lymphoid stroma) and mixed adeno-
neuroendocrine carcinoma. °Based on the number of representative tissues. RGC, remnant gastric cancer; EGC, 
early gastric cancer; LN, lymph node; LVI, lympho-vascular invasion; PNI, peri-neural invasion.
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86). Furthermore, 10.7% of subcutaneous implantations were successful (14 out of 131), while only 3.3% of sub-
renal capsule implantations were successful (1 out of 30), and Matrigel-embedded tumours did not improve the 
engraftment success (11.1% without Matrigel versus 13.6% with Matrigel, p > 0.999, Supplementary Table S3).
Histological and genomic features of PDX tumours. Histological reviews were routinely conducted 
for established PDX tumours. As shown in Fig. 1A, histology (histological type and Lauren classification) of F1 
and F3 PDX tumours (from two representative cases, GA006 and GA013) were well-matched with those of pri-
mary tumours. Using whole exome and RNA sequencing from primary (F0) tumours and F3 PDX tumours, these 
two representative cases were analysed in depth to determine whether genetic features of PDX tumours changed 
during rounds of subgrafting.
To assess the overall genomic changes in PDX tumours, we first investigated whole exome sequencing data 
between F0 and F3 tumours. There were 22 de novo mutations and 15 disappeared mutations in GA006, and 18 
de novo mutations in GA013 PDX tumours (Fig. 1B,C). Many of the de novo and disappeared mutations were 
synonymous variants which unlikely to be deleterious to its protein function. In RNA sequencing analysis, the 
mRNA expression levels of those genes were similar between F0 and F3 (Supplementary Table S4).
Next, to further investigate the genomic differences in cancer relevant genes between the primary and PDX 
tumours, we focused on 726 cancer-related genes (Supplementary Table S5), which were catalogued from 
COSMIC, Foundation Medicine, Oncomine Cancer Research Panel, and TCGA database. As shown in Fig. 2A, 
all the cancer-related genes were stable during establishment and subgrafting of F3 tumours and mRNA sequenc-
ing analysis revealed no significant differences in expression levels between F0 and F3 (Supplementary Table S6). 
When comparing allele frequencies between F0 and F3 tumours, correlation analyses showed that allele frequen-
cies between F0 and F3 tumours were well correlated (r = 0.78, and r = 0.88 for GA006 and GA013, respectively, 
p < 0.001, Fig. 2B). Further, mRNA expression levels of 726 cancer-related genes were well correlated between 
F0 and F3 tumours (r = 0.99 and r = 0.99 for GA006 and GA013, respectively; Fig. 2C,D). In aggregate, these 
in-depth analyses showed that not only mutation profiles of the genes, but also RNA expression levels of corre-
sponding genes analysed by RNA sequencing were stable over subsequent passages.
Intra-generational comparison of PDX tumours. To address the issue of intra-generational hetero-
geneity of PDX tumours, additional analyses were carried out. A thorough histological assessment revealed no 
observable heterogeneity among individual tumours in F3 generation of the two representative PDX cases (24 
and 14 cases of F3 tumours in GA006 and GA013, respectively). In whole exome sequencing analysis, some 
genetic variations in 726 cancer related genes were noticed across five F3 tumours of GA013 case when analysed 
without additional high-quality filters (Supplementary Fig. S2A). When applying high-quality filters including 
sequencing depth and base-call quality, intra-generational genetic variations previously observed were disap-
peared (Supplementary Fig. S2B). In addition, no evident discrepancy in mRNA expression was observed among 
the five F3 tumours of GA013 case based on a correlation analysis of the entire genes as well as 726 cancer related 
genes (Supplementary Fig. S2C,D).
Lymphomatous transformation in PDX tumours. After histological review of all successful cases, we 
found that the histology was not maintained in five cases of F1 PDX tumours (5 out of 15 successful cases). 
In all five cases with histological changes, tumour tissues obtained from F1 mice showed a lymphocytic domi-
nant pattern, regardless of primary tumour histology. Immunohistochemistry (IHC) showed that these tumours 
were cytokeratin (CK) negative, but the cells strongly stained for CD20 and Epstein-Barr virus (EBV) early RNA 
(EBER) by in situ hybridization (ISH), indicating they were related to EBV-associated B-cell lymphoma (Fig. 3). 
Variables
Number (%)
p-valueSuccessful (n = 15) Unsuccessful (n = 47)
Ischemic time* 20 (5–45) 20 (0–70) 0.498
Ex vivo time* 75 (43–167) 135 (44–272) 0.003
PDX time* 17 (8–37) 17 (5–48) 0.895
Overall time* 123 (77–226) 167 (74–357) 0.01
Tumour amount 0.108
 Single piece 8 (53.3) 36 (76.6)
 Multi-piece 7 (46.7) 11 (23.4)
Variables† Successful (n = 15) Unsuccessful (n = 146) p-value
Strain 0.787
 nude 6 (40.0) 69 (47.3)
 NOG 9 (60.0) 77 (52.7)
Implanted site 0.308
 Subcutaneous 14 (93.3) 117 (80.1)
 Subrenal capsule 1 (6.7) 29 (19.9)
Table 3.  Experimental factors related to engraftment success of PDX tumours of gastric cancer. *Minutes. 
†Based on the number of mice. PDX, patient derived xenograft; NOG, NOD/Shi-scid/IL-2 Rγ null mouse.
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These lymphomas were only observed in PDX tumours from the NOG mouse strain (55.6%, 5 out of 9 cases 
of engraftment success for the F1 NOG mice), and no lymphoma transformations were observed in six cases 
of PDX tumours from nude mice (F1). The detailed IHC results of these cases are summarized in Table 4. In 
mouse necropsy, gross tumour metastases were identified in the liver, spleen, kidney, and lymph nodes in four 
out of five cases of lymphoma transformation (except for GA054-1). All of metastatic tumours were confirmed as 
lymphomas by histologic evaluation. In contrast, there were no tumour metastases observed in PDX tumours of 
histologically confirmed adenocarcinomas.
Figure 4 shows an interesting case illustrating the relationship between histological changes to lymphoma and 
the mouse strain. The F1 tumour, which was grown in a NOG mouse showed the same histology compared to the 
F0 tumours. This F1 tumour was sliced and the fragments were implanted into three NOG mice and three nude 
mice (F2). All tumours, which were engrafted into NOG mice (F2) were transformed into lymphomas, while the 
tumours engrafted into nude mice (F2) retained their histology in two cases (engraftment failed in one case). The 
F2 lymphoma from NOG mice succeeded in the F3 generation, and the histology of the lymphoma was retained 
in all NOG mice (n = 7), whereas none of the lymphomas subgrafted into nude mice (n = 7) successfully formed 
tumours. F2 tumours from nude mice with sustained adenocarcinoma histology were implanted into four NOG 
mice and one nude mouse (F3). All of them were successfully engrafted, and the histological characteristics were 
maintained. When classifying lymphoma cases as unsuccessful and again analysing factors, which were correlated 
with engraftment success, the results were similar; Lauren classification (p = 0.022), percentage of tumour cells 
Figure 1. Histologic and genomic features between primary and PDX tumours. (A) Tumour section slides 
were stained to H & E for comparing histology of F1 and F3 PDX tumours with their corresponding F0 tumour 
in two PDX models. a, F0 from GA006; b, F1 from GA006; c, F3 from GA006; d, F0 from GA013; e, F1 from 
GA013; f, F3 from GA013. Scale bars = 100 μm. (B,C) De novo and disappeared mutations between F0 and F3 
PDX tumours of GA006 (B) and GA013 (C) models. De novo mutations are defined as total allele count being 
zero in the F0 and greater than or equal to five in F3. The opposite cases are disappeared mutations.
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(p = 0.044), and ex vivo time (p = 0.013) correlated with engraftment success (n = 10), but overall procedure time 
was not statistically significant (p = 0.054).
Discussion
Retaining histological and genetic features of the patient tumour is the most important aspect of PDX models. It 
has been reported that the histology of primary tumours (F0) was maintained through successive generations in 
various cancers, including gastric cancer13,20–24, which is consistent with the results of the present study. In addi-
tion, our sequencing analyses showed that the genetic features of PDX tumours, in terms of mutation profiles, 
allele frequencies, and RNA expression levels, correlated well with the corresponding tumour when histology 
was maintained. Consistent genetic features of PDX tumour models compared to primary tumours have been 
reported in other studies13,22,23,25–29. However, some genes were newly identified or disappeared in PDX tumours, 
compared to primary tumours, as reported in other cancer types using the PDX model30. Those differences were 
thought to be caused by heterogeneity of the primary tumour (the region of the primary tumour for the PDX 
tumour and extraction of DNA or RNA differed) and/or selection pressures arising during engraftment into 
different species (from human to mouse)30. In the present results, we demonstrated that genomic differences 
between PDX and primary tumours as well as among individual tumours in the same generation were insignifi-
cant, especially for well-known cancer-related genes. Thus, the PDX tumour model can constitute a paraclinical 
model that retains tumour characteristics of the original patient. Therefore PDX models can be used in cancer 
research and development of potential cancer therapeutics.
In the present study, we identified parameters correlated with engraftment success, to improve the success rate 
of future PDX tumour models. We found that ex vivo time and overall procedure time were the only significant 
experimental parameters affecting the success of establishing PDX tumour models for gastric cancer. Ischemic 
injury is closely related to viability of cells, and associated with low survival of grafts in organ transplantation31–33. 
Our results also indicate the importance of reducing ischemic time for successful engraftment of viable cancer 
cells. To the best of our knowledge, only one previous study has investigated this issue in PDX tumours, reporting 
Figure 2. Correlation of genetic features for 726 cancer-related genes between primary and PDX tumours. 
(A) Mutations in F0 and F3 tumours among 726 cancer-related genes were indicated in GA006 (dark blue 
bars) and GA013 (red bars) PDX models. (B) Mutant allele frequencies between F0 and F3 tumours for 14 
and 7 mutations detected in GA006 (blue dots) and GA013 (red dots) PDX models, respectively. (C,D) The 
correlation of mRNA expression levels for 726 cancer-related genes in F0 and F3 tumours was represented as 
scatter plot in GA006 (C) and GA013 (D) PDX models.
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that time to engraftment was not related to engraftment success34. However, this study used different types of 
tumours, and classified the time to engraftment into early (on the day of surgery or the next day) and delayed (two 
days after surgery) times, without additional information in detail. Other experimental factors, such as implanta-
tion site (subcutaneous vs. subrenal capsule)13,18,35, using Matrigel36,37, and more immunocompromised mice18,38, 
were reported to improve the success rate of the PDX tumour model in various cancers. However, those factors 
did not improve the success of PDX tumours in the present study. The possible reasons for this difference may 
involve the use of different types of cancers. In addition, most of the previous studies were not direct comparisons 
between nude and NOG strains.
Tumour aggressiveness involving metastatic tumours, lymph node metastases, and poorly differentiated his-
tology has been reported to be related to engraftment success for colon cancer27,39. However, in the current study, 
tumour staging and the degree of differentiation were not related to engraftment success. Because previous stud-
ies of gastric cancer PDX tumour models reported similar results29,40, we postulate that the degree of tumour 
heterogeneity in gastric cancers is much higher than other reported cancers. Clinically subdominant clones in the 
tumour could be selected in vivo, giving rise to xenograft tumour formation. As high failure rates in some histo-
logic subtypes of PDX tumour models have been reported18, the Lauren classification and tumour cell percentage 
Figure 3. Representative histology of lymphoma transformed PDX tumours. (A) F0 tumour section slides 
were stained by H & E. (B) F1 tumour section slides were stained by H & E. (C) Cytokeratin, as a marker of 
epithelial tumour cells, was not detected by immunohistochemistry in F1 tumour. (D) CD3, as a marker of 
T cells, was infrequently detected by immunohistochemistry in F1 tumour. (E) CD20, as a marker of B cells, 
was detected by immunohistochemistry in F1 tumour. (F) Epstein-Barr encoded RNA was detected by in situ 
hybridization in F1 tumour. Scale bars = 50 μm.
Case No. Histology
F1 mouse
Strain Mirror histology EBER CK (AE1/AE3) CD20 CD3
GA001 Mixed NOG B cell lymphocyte Positive Negative Positive Negative
GA018 PD NOG B cell lymphocyte Positive Negative Positive Negative
GA054-1 MD NOG B cell lymphocyte Positive Negative Positive Negative
GA054-2 PD NOG B cell lymphocyte Positive Negative Positive Positive
GA061 MD with SRC component NOG B cell lymphocyte Positive Negative Positive Negative
Table 4.  Summary of cases where tumour histology was changed into EBV-related B-cell lymphoma. MD, 
moderately differentiated tubular adenocarcinoma; PD, poorly differentiated tubular adenocarcinoma; SRC, 
signet ring cell; NOG, NOD/Shi-scid/IL-2 Rγ null mouse; EBER, Epstein-Barr virus-encoded RNA in situ 
hybridization; CK, cytokeratin.
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were shown in the present study to be related to engraftment success. The diffuse type of gastric cancer was 
correlated with low success rate, which was consistent with a previous report29. In the case of diffuse type gastric 
cancers, tumour cells are dispersed into the stromal tissue, and the number of tumour cells is lower per unit area, 
making it unfavourable factor for successful engraftment. Based upon our results, the tumour cell percentage of 
the diffuse type was less than the intestinal or mixed/indeterminate (others) types (24.4 ± 21.4% for the diffuse 
type, 47.0 ± 28.7% for the intestinal type, and 41.0 ± 26.3% for others, both p = 0.001), which is supportive of this 
possibility. According to a recent study of the molecular characteristics for gastric cancer, mesenchymal-like gas-
tric cancer comprised mostly (80.4%) of the diffuse type, by the Lauren classification, has the worst prognosis41. 
When considering that the PDX tumour is most needed for modelling tumours with poor prognoses, establishing 
the diffuse type gastric cancer PDX tumour model might be especially challenging.
Figure 4. Schematic drawing of sequential histological changes into lymphomas according to the mouse 
strain during subpassaging in PDX model. (A) An engrafted adenocarcinoma in an F1 NOG mouse changed 
into a lymphoma in F2 NOG mice. It was retained in F3 NOG mice, but was not engrafted into F3 nude mice. 
However, an adenocarcinoma engrafted from an F1 NOG mouse into F2 nude mice retained their histology, and 
the tumour was not changed into a lymphoma in an F3 nude mouse as well as in F3 NOG mice. (B) Each section 
slide of primary and PDX tumour during subpassaging was stained by H & E for comparing their histological 
changes. a, adenocarcinoma in a primary tumour; b, adenocarcinoma in an F1 NOG mouse; c, lymphoma in 
an F2 NOG mouse; d, adenocarcinoma in an F2 nude mouse; e, lymphoma in an F3 NOG mouse; f, no tumour 
growth in an F3 nude mouse from an F2 NOG mouse; g, adenocarcinoma in an F3 NOG mouse from an F2 
nude mouse; h, adenocarcinoma from an F3 nude mouse from an F2 nude mouse. Scale bars = 100 μm. *from 
F2 NOG mice, †from F2 nude mice.
www.nature.com/scientificreports/
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EBV-related B-cell lymphomas in up to 68% of PDX tumour models have been recently reported in vari-
ous types of cancer37,42–45, which used NOD/SCID46, NSG47, and NOG48 strains of mice. A possible explanation 
for the lymphoma transformation in PDX tumours might involve EBV-infected B-cells in the host (primary 
tumours from patients), which are latent, but can be activated because they are free from immune cell surveil-
lance when implanted into immune-compromised mice; this is similar to the development of lymphomas in 
immune-compromised patients49. Because H. pylori-related gastritis is associated with gastric cancer50, the extent 
of baseline inflammation in gastric cancer is higher than in other tumours. As a result, the incidence of lymphoma 
in the PDX tumour model is higher in gastric cancer than other tumours42. In the present study, 33.3% of success-
ful cases involved lymphoma, and all the lymphomas occurred in NOG mice (F1). Also, despite histological char-
acteristics being retained in F1 mice, it could be changed into lymphoma in subsequent grafts if it was implanted 
into the NOG strain (F2). One intriguing observation is that lymphoma could not survive in nude mice. If the 
tumour was engrafted into nude mice, it did not change into lymphomas again in subsequent grafts, even when 
it was implanted into NOG mice (Fig. 4). It is possible that nude mice have natural killer cells that interfere with 
the reactivation of latent EBV, resulting in resistance to lymphoma transformation of the xenografted tumour47. 
It has been suggested that rituximab, a monoclonal antibody against B-cells, be used to treat mice to prevent lym-
phomas in the PDX tumour model48. However, there is no effective solution to prevent and predict EBV-related 
B-cell lymphomas yet. To the best of our knowledge, our study is the first to compare the results of different 
mouse strains using the gastric cancer PDX tumour model. We could not find any advantages of NOG mice over 
nude mice, and the overall success rates were not significant (10.5% for NOG mice versus 8.0% for nude mice, 
p = 0.787). Furthermore, 55.6% of the engraftment successes for NOG mice involved lymphoma, and the growth 
rate of the tumour was not different between NOG and nude strains in our series (Supplementary Fig. S1). Thus, 
we suggest that for the F1 generation, nude mice are sufficient for the gastric cancer PDX tumour model.
In summary, PDX tumours from surgical specimens of gastric cancer were successfully established in 
immune-compromised mice. Reducing ex vivo time improved the success of engraftment. Transformation to 
lymphoma and low success rates for diffuse type tumours were the challenges in establishing the PDX tumour 
model for gastric cancer. Histological and genetic similarities of the PDX model to the corresponding primary 
tumour demonstrated that the PDX tumour model can be translated into clinical practice for the development of 
effective personalized therapeutics for gastric cancer.
Materials and Methods
Patient selection. This study was approved by the Institutional Review Board (IRB) of Yonsei University 
Severance Hospital (4-2013-0526), and all patients provided written informed consent. All protocols adhered to 
the tenets of the Declaration of Helsinki. The samples were obtained from patients with pathologically proven 
adenocarcinoma of the stomach, with the following characteristics: 1) the size of the tumour was larger than 
4 cm, because it should be large enough not to affect the pathological staging of the patient, 2) not only primary 
gastric cancer but also cancer in the remnant stomach was used; patients who were treated preoperatively with 
chemotherapy or chemoradiation therapy were also included, 3) if the patient received gastrectomy with metas-
tasectomy for a metastatic lesion, both primary and metastatic tissue were obtained, and 4) patients with human 
immunodeficiency virus, hepatitis B, and/or hepatitis C virus were excluded.
Tissue sampling. The tumour was obtained from a surgical specimen (F0) just after gastrectomy. A total 
of six pieces of tumour tissue were collected from each patient under sterile conditions. They were separated 
into two groups (three paired tissues in both groups): one group for the PDX tumour model in nude mice and 
another group for the PDX tumour model in NOG mice. In each group, there were three paired tissues: 1) tis-
sue for the PDX tumour model was placed into RPMI 1640 medium with antibiotics (penicillin, streptomycin, 
gentamicin, and amphotericin B); 2) other tissue was cryopreserved in liquid nitrogen and stored at − 80 °C; and 
3) other tissue was fixed in 10% formalin solution for hematoxylin and eosin (H & E) staining as a representative 
histopathological characterisation of the implanted tumour. Each time point, such as the time of last ligation of 
the main artery, gastrectomy, and the beginning and completion of the PDX, was recorded to analyse the effect of 
processing time on engraftment success of the PDX tumour.
Establishment of the PDX tumour model. The mice were cared according to the institutional guidelines 
for animal care. All animal experiments were approved by the Institutional Animal Care and Use Committee 
(IACUC) of the Yonsei University College of Medicine (2014-0130). The 6-week-old female athymic nude mice 
(Japan SLC, Inc., JAPAN) and male NOG mice (NOD/Shi-scid, IL-2 Rγ null, CIEA, JAPAN) were used for each 
PDX model. Before the experiments, the animals were acclimated for seven days with 12 hour light-dark cycles. 
The transferred tumour was placed into a sterile Petri dish containing phosphate-buffered saline (PBS), then 
sliced into 3 × 3 × 3 mm3 fragments. Typically, each fragment was implanted into a subcutaneous area in the 
right and left flanks. They were also implanted into the subrenal capsule (under the renal capsule) from the 
16th PDX case, because it was reported that subrenal capsule implantation shortened time to engraftment and 
improved the engraftment success13,18,35. Initially, Matrigel was not used, and only a single piece of tumour tis-
sue was used for implantation. Thereafter, Matrigel-embedded tumours were tried from the 46th PDX case and 
multiple pieces of tumours (4 ~ 6 pieces of 3 × 3 × 3 mm3 fragments) were tried from the 39th PDX case and the 
number of pieces were decided according to the size of the donor tumours. The size of the implanted tumour 
was checked 1 ~ 3 times per week using Vernier calipers when the implanted tissue was palpable, and the volume 
was calculated as (length × width2)/2. For follow-up of subrenal capsule PDX model tumours, non-enhanced 
magnetic resonance imaging (MRI) [Bruker Preclinical Animal MRI (9.4 T)] was used at 1–2 month intervals. 
Tumour formation in the implanted site over 500 mm3 in size was considered as engraftment success in the case 
of subcutaneous implantation, and tumour formation growth (detected by MRI) was regarded as successful for 
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subrenal implantation. For the engraftment success cases, the mouse was anaesthetised and the tumour (F1) was 
removed for serial transplantation to the next generation (F2, F3). After removing the tumour, the mouse was 
sacrificed by cervical dislocation and necropsy was done to determine possible tumour metastasis.
Histological evaluation of primary and PDX tumours. Sections (4 μm thick) from formalin-fixed and 
paraffin-embedded blocks were prepared for IHC and Epstein-Barr encoded RNA in situ hybridization (EBER 
ISH). IHC was performed using a Ventana XT automated stainer (Ventana Corporation, Tucson, AZ, USA) with 
antibodies against CK (1:300, AE1/AE3; DAKO, Carpinteria, CA, USA), CD3 (1:100, DAKO), and CD20 (1:1600, 
DAKO). Every other week, there was a regular meeting with the surgeon, the pathologist, and researchers for 
reviewing and discussion of the histopathological characteristics of each tumour.
Clinical and experimental information. Clinical and pathological information about enrolled patients 
was collected prospectively. The following variables were analysed to identify factors which were related to engraft-
ment success of the PDX tumour model: 1) the patient’s age, patient’s sex, history of diabetes mellitus, history of 
hypertension, history of tuberculosis, history of smoking and alcohol, blood type, preoperative tumour markers 
[CEA and carbohydrate antigen (CA) 19-9], white blood cell count, percentage of neutrophils and lymphocytes, 
neutrophil lymphocyte ratio (NLR), and albumin level; 2) tumour pathological characteristics including size, 
location, gross type, tumour depth, presence of lymph node metastasis, and pTNM stage according to the 7th edi-
tion of the UICC51, Lauren classification19, presence of lympho-vascular and perineural invasion, history of pre-
operative chemotherapy, and histology and tumour percentage in the representative tissue; and 3) experimental 
information including ischemic time (from last ligation of the main vessel to gastrectomy, Supplementary Fig. S3), 
ex vivo time (from gastrectomy to beginning of the PDX), the PDX time (from beginning to end of the PDX), and 
overall procedure time (ischemic time + ex vivo time + the PDX time), strain of mouse, amount of tumour and 
its implantation site, and whether Matrigel was used for analysis.
Whole exome and whole RNA sequencing. For genomic analyses, two representative cases (GA006 
and GA013) were selected considering two criteria: 1) PDX cases passaged greater than F3 generation at the time 
of analysis, 2) PDX cases representing early and advanced stage of tumours because they might have different 
genomic landscapes.
Genomic DNA and total RNA were extracted from the frozen tissues of primary and PDX tumour model tis-
sues using the DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA, USA) and the RNeasy Plus Mini Kit (Qiagen) 
according to the manufacture’s protocols. The quality of DNA was checked by 1% agarose gel electrophoresis and 
by the PicoGreen® dsDNA Assay (Invitrogen, Carlsbad, CA, USA). For whole exome sequencing, SureSelect 
sequencing libraries were prepared according to the manufacturer’s instructions (Agilent Sureselect All Exon V4 
kit, Santa Clara, CA, USA) using the Bravo automated liquid handler. For RNA sequencing, library preparations 
were performed using the Illumina™ Truseq RNA Access Library Prep Kit (Illumina™, San Diego, CA, USA) 
according to manufacturer’s protocols. The library qualities of both whole exome and RNA sequencing were 
verified by capillary electrophoresis (Bioanalyzer, Agilent). After qPCR using the SYBR Green PCR Master Mix 
(Applied Biosystems, Waltham, MA, USA), index-tagged libraries were combined in equimolar amounts in the 
pool. Cluster generation occurred in the flow cell on the cBot automated cluster generation system (Illumina™). 
The flow cell loaded on the HISEQ 2500 sequencing system (Illumina™) performed sequencing with 2 × 100 base 
pair (bp) read lengths.
Data analyses. Continuous variables were presented with median range and analysed by the Mann-Whitney 
U-test. Categorical variables were presented with number and percentage and analysed by Fisher’s exact test. A 
p-value less than 0.05 was considered statistically significant. The analyses were performed by SPSS, version 19.0 
software for Windows (SPSS, Chicago, IL, USA). A total of 727 cancer-related genes (Supplementary Table S5) 
were collected from COSMIC (Catalogue of Somatic Mutations in Cancer, n = 522), Foundation Medicine 
(n = 314), the Oncomine Cancer Research Panel (n = 202), and the TCGA Hotspot (n = 16), and used to com-
pare genetic features between primary tumours (F0) and the PDX tumours (F3). We defined mutations including 
all sequence variants regardless of synonymous or non-synonymous alterations.
We built a new reference genome combining the human and mouse reference genomes52; to this reference 
genome, we aligned whole exome sequencing information by using Burrows–Wheeler Aligner software53. To 
avoid mouse contamination, we excluded aligned sequences from the mouse reference genomes. Then, we 
removed duplicated reads by using SAMtools54. We called somatic mutations, including single nucleotide var-
iants and small insertions/deletions using Virmid55 and muTect56 (Supplementary Fig. S4). To determine the 
potential functional consequences of detected variants, we annotated them using VEP (ENSEMBL’s Variant Effect 
Predictor)57. To determine high-confidence variants, bidirectionality was included as a parameter for variants 
selection and all the variants called were manually inspected with Integrative Genomics Viewer (IGV). Called 
somatic mutations against control were further filtered based on sequencing depth and base-call quality (≥ 20 
of high quality depth and ≥ 5 total allele counts)58,59 in both F0 and F3 tumours in 726 cancer related genes. To 
define de novo and disappeared mutations, mutations were filtered with ≥ 20 of high quality depth in both F0 and 
F3; if allele frequency was zero in the primary tumour but the total allele count of F3 was greater than or equal 
to five, it was considered de novo mutations, and the opposite cases were considered disappeared mutations. 
RNA sequencing data from the Illumina™ FASTQ format were assigned to human transcripts using the Xenome 
tool60. Human transcript data were then processed with the Tophat-Cufflinks pipeline. We aligned reads to the 
genome with TOPHAT and used Cufflinks for transcriptome assembling, and Cuffdiff script from Cufflinks was 
used for gene expression analysis with the -classic-fpkm option. Then, we used CummeRbund to visualize RNA 
sequencing analysis results.
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